Targacept announced the initiation of a Phase 2 exploratory study of TC-5214 for the treatment of resistant hypertension. This study is a double-blind, placebo-controlled trial of approximately 12 subjects with resistant hypertension. Patients will receive either a single escalating dose of TC-5214 or placebo once per week for four weeks, followed by a fixed daily dose of TC-5214 or placebo over the next two weeks.
TC-5214 is an investigational nicotinic channel blocker being studied as augmentation therapy for treatment-resistant hypertension.
For more information call (336) 480-2100 or visit www.targacept.com.